Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Capital Expenditures (2018 - 2023)

Marker Therapeutics (MRKR) has disclosed Capital Expenditures for 6 consecutive years, with $141979.0 as the latest value for Q1 2023.

  • On a quarterly basis, Capital Expenditures fell 93.9% to $141979.0 in Q1 2023 year-over-year; TTM through Mar 2023 was -$2.1 million, a 149.87% decrease, with the full-year FY2022 number at $57607.0, down 97.33% from a year prior.
  • Capital Expenditures was $141979.0 for Q1 2023 at Marker Therapeutics, up from -$24691.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.5 million in Q2 2020 to a low of -$2.3 million in Q2 2022.
  • A 5-year average of $236041.8 and a median of $66170.0 in 2022 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: surged 1233.58% in 2020, then plummeted 3741.79% in 2022.
  • Marker Therapeutics' Capital Expenditures stood at -$223126.0 in 2019, then tumbled by 220.28% to -$714619.0 in 2020, then surged by 392.51% to $2.1 million in 2021, then crashed by 101.18% to -$24691.0 in 2022, then soared by 675.02% to $141979.0 in 2023.
  • Per Business Quant, the three most recent readings for MRKR's Capital Expenditures are $141979.0 (Q1 2023), -$24691.0 (Q4 2022), and $66170.0 (Q3 2022).